In the Phase III EPCORE FL-1 trial of epcoritamab plus R² in R/R follicular lymphoma, what CRS profile was seen after the step-up dosing schedule was changed during the trial?
With a two-step-up dosing regimen, grade 2 CRS occurred in about 5% of patients and grade 3 CRS in about 1%.
With a three-step-up dosing regimen, grade 2 CRS occurred in about 5% of patients, with no grade 3 or 4 CRS.
With a three-step-up dosing regimen, CRS was eliminated entirely, so no inpatient monitoring infrastructure is needed.